Patents by Inventor Rajesh Devraj

Rajesh Devraj has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyridine derivatives
    Patent number: 8809372
    Abstract: The present application provides novel pyridine compounds and pharmaceutically acceptable salts or prodrugs thereof. Also provided are methods for preparing these compounds. These compounds are useful in inhibiting CYP17 activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with CYP17 activity. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer, such as prostate cancer.
    Type: Grant
    Filed: September 30, 2012
    Date of Patent: August 19, 2014
    Assignee: Asana Biosciences, LLC
    Inventors: Roger Astbury Smith, Nicholas James Laping, Aranapakam M. Venkatesan, Raghava Reddy Kethiri, Chandregowda Venkateshappa, Bheemashankar Kulkarni, Purushottam Dewang, Rajendra Kristam, Rajesh Devraj
  • Tricyclic compounds, compositions and methods
    Patent number: 7786097
    Abstract: The present invention is directed to compounds of Formula I: or salt thereof, which are modulators of the glucocorticoid receptor. The compounds and salts of the invention are useful in the treatment of conditions mediated by glucocorticoid receptor activity.
    Type: Grant
    Filed: July 21, 2009
    Date of Patent: August 31, 2010
    Assignee: Pfizer Inc.
    Inventors: Hengmiao (Henry) Cheng, Rajesh Devraj, Gary A Decresenzo, Xiao Hu, Kevin D. Jerome, Mark Obukowicz, Lisa Olson, Paul V. Rucker, Ronald Keith Webber
  • Diaryl substituted pyridinones
    Patent number: 7629363
    Abstract: Disclosed are compounds Formula I and pharmaceutically acceptable salts thereof, wherein R1, R2, R3/R4, and R5 are defined herein. These compounds are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical compositions containing the compounds, methods of preparing the compounds and methods of treatment using the compounds are also disclosed.
    Type: Grant
    Filed: September 14, 2005
    Date of Patent: December 8, 2009
    Assignee: Pfizer Inc
    Inventors: Balekudru Devadas, John Walker, Shaun R. Selness, Terri L. Boehm, Richard C. Durley, Rajesh Devraj, Brian S. Hickory, Paul V. Rucker, Kevin D. Jerome, Heather M. Madsen, Edgardo Alvira, Michele A. Promo, Radhika M. Blevis-Bal, Laura D. Marruto, Jeff Hitchcock, Thomas Owen, Win Naing, Li Xing, Huey S. Shieh, Aruna Sambandam, Shuang Liu, Ian L. Scott, Kevin F. McGee
  • TRICYCLIC COMPOUNDS, COMPOSITIONS AND METHODS
    Publication number: 20090281148
    Abstract: The present invention is directed to compounds of Formula I: or salt thereof, which are modulators of the glucocorticoid receptor. The compounds and salts of the invention are useful in the treatment of conditions mediated by glucocorticoid receptor activity.
    Type: Application
    Filed: July 21, 2009
    Publication date: November 12, 2009
    Applicant: Pfizer,Inc.
    Inventors: Hengmiao (Henry) Cheng, Rajesh Devraj, Gary A. Decresenzo, Xiao Hu, Kevin D. Jerome, Mark Obukowicz, Lisa Olson, Ronald Keith Webber
  • Tricyclic compound, compositions, and methods
    Patent number: 7598231
    Abstract: The present invention is directed to compounds of Formula I: or salt thereof, which are modulators of the glucocorticoid receptor. The compounds and salts of the invention are useful in the treatment of conditions mediated by glucocorticoid receptor activity.
    Type: Grant
    Filed: January 31, 2008
    Date of Patent: October 6, 2009
    Assignee: Pfizer, Inc.
    Inventors: Hengmiao (Henry) Cheng, Rajesh Devraj, Gary A DeCresenzo, Xiao Hu, Kevin D. Jerome, Mark Obukowicz, Lisa Olson, Paul V. Rucker, Ronald Keith Webber
  • Tricyclic Compound, Compositions, and Methods
    Publication number: 20080188443
    Abstract: The present invention is directed to compounds of Formula I: or salt thereof, which are modulators of the glucocorticoid receptor. The compounds and salts of the invention are useful in the treatment of conditions mediated by glucocorticoid receptor activity.
    Type: Application
    Filed: January 31, 2008
    Publication date: August 7, 2008
    Applicant: Pfizer, Inc.
    Inventors: Hengmiao (Henry) Cheng, Rajesh Devraj, Gary A. DeCresenzo, Xiao Hu, Kevin D. Jerome, Mark Obukowicz, Lisa Olson, Paul V. Rucker, Ronald Keith Webber
  • Diaryl Substituted Pyridinones
    Publication number: 20070088033
    Abstract: Disclosed are compounds Formula I and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and R5 are defined herein. These compounds are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical compositions containing the compounds, methods of preparing the compounds and methods of treatment using the compounds are also disclosed.
    Type: Application
    Filed: September 13, 2006
    Publication date: April 19, 2007
    Inventors: Balekudru Devadas, John Walker, Shaun Selness, Terri Boehm, Richard Durley, Rajesh Devraj, Brian Hickory, Paul Rucker, Kevin Jerome, Heather Madsen, Edgardo Alvira, Michele Promo, Radhika Blevis-Bal, Laura Marruto, Jeff Hitchcock, Thomas Owen, Win Naing, Li Xing, Huey Shieh, Aruna Sambandam, Shuang Liu, Ian Scott, Kevin McGee
  • Substituted pyrazoles as p38 kinase inhibitors
    Publication number: 20070078146
    Abstract: A class of pyrazole derivatives is described for use in treating p38 kinase medicated disorders. Compounds of particular interest are defined by Formula IA wherein R1, R2, R3 and R4 are as described in the specification.
    Type: Application
    Filed: May 5, 2004
    Publication date: April 5, 2007
    Inventors: Ashok Naraian, Michael Clare, Paul Collins, Joyce Crich, Rajesh Devraj, Daniel Flynn, Lifeng Geng, Matthew Graneto, Cathleen Hanau, Gunnar Hanson, Susan Hartmann, Michael Hepperle, He Huang, Ish Khanna, Francis Koszyk, Shuyuan Liao, Suzanne Metz, Win Naing, Richard Partis, Thao Perry, Shashidhar Rao, Shaun Selness, Michael South, Michael Stealey, John Talley, Michael Vazquez, John Walker, Richard Weier, Xiangdong Xu, Syaulan Yang, Yi Yu
  • Substituted pyrazoles as p38 kinase inhibitors
    Patent number: 7153959
    Abstract: A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula IA wherein R1, R2, R3 and R4 are as described in the specification.
    Type: Grant
    Filed: February 25, 2003
    Date of Patent: December 26, 2006
    Assignee: Pharmacia Corporation
    Inventors: Ashok S. Naraian, Michael Clare, Paul W. Collins, Joyce Zuowu Crich, Rajesh Devraj, Daniel L. Flynn, Lifeng Geng, Matthew J. Graneto, Cathleen E. Hanau, Gunnar J. Hanson, Susan J. Hartmann, Michael Hepperle, He Huang, Francis J. Koszyk, Shuyuan Liao, Suzanne Metz, Richard A. Partis, Thao D. Perry, Shashidhar N. Rao, Shaun Raj Selness, Michael S. South, Michael A. Stealey, John Jeffrey Talley, Michael L. Vazquez, Richard M. Weier, Xiangdong Xu, Ish K. Khanna, Yi Yu, Win Naing, Syaulan Yang
  • Diaryl substituted pyridinones
    Publication number: 20060211694
    Abstract: Disclosed are compounds Formula I and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and R5 are defined herein. These compounds are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical compositions containing the compounds, methods of preparing the compounds and methods of treatment using the compounds are also disclosed.
    Type: Application
    Filed: September 14, 2005
    Publication date: September 21, 2006
    Applicant: Pharmacia Corporation, Global Patent Department
    Inventors: Balekudru Devadas, John Walker, Shaun Selness, Terri Boehm, Richard Durley, Rajesh Devraj, Brian Hickory, Paul Rucker, Kevin Jerome, Heather Madsen, Edgardo Alvira, Michele Promo, Radhika Blevis-Bal, Laura Marruto, Jeff Hitchcock, Thomas Owen, Win Naing, Li Xing, Huey Shieh, Aruna Sambandam, Shuang Liu, Ian Scott, Kevin McGee
  • Substituted pyrazoles as p38 kinase inhibitors
    Patent number: 7071198
    Abstract: A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula IA wherein R1, R2, R3 and R4 are as described in the specification.
    Type: Grant
    Filed: May 5, 2004
    Date of Patent: July 4, 2006
    Assignee: Pharmacia Corporation
    Inventors: Ashok S. Naraian, Michael Clare, Paul W. Collins, Joyce Zuowu Crich, Rajesh Devraj, Daniel L. Flynn, Lifeng Geng, Matthew J. Graneto, Cathleen E. Hanau, Gunnar J. Hanson, Susan J. Hartmann, Michael Hepperle, He Huang, Ish K. Khanna, Francis J. Koszyk, Shuyuan Liao, Suzanne Metz, Win Naing, Richard A. Partis, Thao D. Perry, Shashidhar N. Rao, Shaun Raj Selness, Michael S. South, Michael A. Stealey, John Jeffrey Talley, Michael L. Vazquez, John Walker, Richard M. Weier, Xiangdong Xu, Syaulan Yang, Yi Yu
  • Substituted pyridinones
    Patent number: 7067540
    Abstract: Disclosed are compounds Formula I and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and R5 are defined herein. These compounds are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical compositions containing the compounds, methods of preparing the compounds and methods of treatment using the compounds are also disclosed.
    Type: Grant
    Filed: February 14, 2003
    Date of Patent: June 27, 2006
    Assignee: Pharmacia Corporation
    Inventors: Balekudru Devadas, John Walker, Shaun R. Selness, Terri L. Boehm, Richard C. Durley, Rajesh Devraj, Brian S. Hickory, Paul V. Rucker, Kevin D. Jerome, Heather M. Madsen, Edgardo Alvira, Michele A. Promo, Radhika M. Blevis-Bal, Laura D. Marruto, Jeff Hitchcock, Thomas Owen, Win Naing, Li Xing, Huey S. Shieh, Aruna Sambandam, Shuang Liu, Ian L. Scott, Kevin F. McGee
  • Substituted pyrazoles as p38 kinase inhibitors
    Patent number: 6979686
    Abstract: A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula (IA), wherein R1, R2, R3 and R4 are as described in the specification.
    Type: Grant
    Filed: December 7, 2001
    Date of Patent: December 27, 2005
    Assignee: Pharmacia Corporation
    Inventors: Ashok S. Naraian, Michael Clare, Paul W. Collins, Joyce Zuowu Crich, Rajesh Devraj, Daniel L. Flynn, Lifeng Geng, Matthew J. Graneto, Cathleen E. Hanau, Gunnar J. Hanson, Susan J. Hartmann, Michael Hepperle, He Huang, Francis J. Koszyk, Shuyuan Liao, Suzanne Metz, Richard A. Partis, Thao D. Perry, Shashidhar N. Rao, Shaun Raj Selness, Michael S. South, Michael A. Stealey, John Jeffrey Talley, Michael L. Vazquez, Richard M. Weier, Xiangdong Xu, Ish K. Khanna, Yi Yu, Win Naing, John Walker, Syaulan Yang
  • Substituted pyridazinones
    Publication number: 20050256122
    Abstract: Disclosed are substituted pyridazinones that are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical composition containing the pyridazinone compounds, methods of preparing the compounds and methods of treatment using the compounds are also disclosed.
    Type: Application
    Filed: March 1, 2005
    Publication date: November 17, 2005
    Inventors: Michael Hepperle, Kevin Jerome, John Walker, Shaun Selness, Rajesh Devraj
  • Substituted pyridinones
    Publication number: 20050176775
    Abstract: Disclosed are compounds of Formula I and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and R5 are defined herein. These compounds are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical compositions containing the compounds, methods of preparing the compounds and methods of treatment using the compounds are also disclosed.
    Type: Application
    Filed: August 13, 2004
    Publication date: August 11, 2005
    Inventors: Balekudru Devadas, John Walker, Shaun Selness, Terri Boehm, Richard Durley, Rajesh Devraj, Brian Hickory, Paul Rucker, Kevin Jerome, Heather Madsen, Edgardo Alvira, Michele Promo, Radhika Blevis-Bal, Laura Marrufo, Jeff Hitchcock, Thomas Owen, Win Naing, Li Xing, Huey Shieh, Aruna Sambandam, Shuang Liu, Ian Scott, Kevin McGee
  • Substituted pyridazinones
    Publication number: 20050020594
    Abstract: Disclosed are substituted pyridazinones that are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical composition containing the pyridazinone compounds, methods of preparing the compounds and methods of treatment using the compounds are also disclosed.
    Type: Application
    Filed: July 16, 2004
    Publication date: January 27, 2005
    Inventors: Michael Hepperle, Kevin Jerome, John Walker, Shaun Selness, Rajesh Devraj
  • Substituted pyrazoles as p38 kinase inhibitors
    Publication number: 20040176433
    Abstract: A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders.
    Type: Application
    Filed: February 25, 2003
    Publication date: September 9, 2004
    Inventors: Ashok S. Naraian, Michael Clare, Paul W. Collins, Joyce Zuowu Crich, Rajesh Devraj, Daniel L. Flynn, Lifeng Geng, Matthew J. Graneto, Cathleen E. Hanau, Gunnar J. Hanson, Susan J. Hartmann, Michael Hepperle, He Huang, Francis J. Koszyk, Shuyuan Liao, Suzanne Metz, Richard A. Partis, Thao D. Perry, Shashidhar N. Rao, Shaun Raj Selness, Michael S. South, Michael A. Stealey, John Jeffrey Talley, Michael L. Vazquez, Richard M. Weier, Xiangdong Xu, Ish K. Khanna, Yi Yu, Win Naing, Syaulan Yang
  • Substituted pyridazinones
    Publication number: 20040142932
    Abstract: 1
    Type: Application
    Filed: January 21, 2003
    Publication date: July 22, 2004
    Inventors: Michael Hepperle, Kevin D. Jerome, John Walker, Shaun Selness, Rajesh Devraj
  • Substituted pyridinones
    Publication number: 20040058964
    Abstract: Disclosed are compounds Formula I 1
    Type: Application
    Filed: February 14, 2003
    Publication date: March 25, 2004
    Inventors: Balekudru Devadas, John Walker, Shaun R. Selness, Terri L. Boehm, Richard C. Durley, Rajesh Devraj, Brian S. Hickory, Paul V. Rucker, Kevin D. Jerome, Heather M. Madsen, Edgardo Alvira, Michele A. Promo, Radhika M. Blevis-Bal, Laura D. Marruto, Jeff Hitchcock, Thomas Owen, Win Naing, Li Xing, Huey S. Shieh, Aruna Sambandam, Shuang Liu, Ian L. Scott, Kevin F. McGee
  • Substituted pyrazoles as p38 kinase inhibitors
    Patent number: 6617324
    Abstract: A class of pyrazole derivatives described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula IA wherein R1, R2, R3 and R4 are as described in the specification.
    Type: Grant
    Filed: April 2, 2002
    Date of Patent: September 9, 2003
    Assignee: G. D. Searle & Company
    Inventors: Ashok S. Naraian, Michael Clare, Paul W. Collins, Joyce Zuowu Crich, Rajesh Devraj, Daniel L. Flynn, Lifeng Geng, Matthew J. Graneto, Cathleen E. Hanau, Gunnar J. Hanson, Susan J. Hartmann, Michael Hepperle, He Huang, Francis J. Koszyk, Shuyuan Liao, Suzanne Metz, Richard A. Partis, Thao D. Perry, Shashidhar N. Rao, Shaun Raj Selness, Michael S. South, Michael A. Stealey, John Jeffrey Talley, Michael L. Vazquez, Richard M. Weier, Xiangdong Xi, Ish K. Khanna, Yi Yu